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ABSTRACT 
TB and HIV are immuno-pathologically interacting epidemic infectious diseases affecting the lives of millions 
globally & sub-Saharan African region accounts the highest burden of both diseases.  Although effective therapies 
are available for the management of each, TB-HIV co-treatment has faced challenges mainly due to drug-drug 
interactions & overlapping drug toxicities. To overcome these, efavirenz (EFV) based highly active antiretroviral 
therapy (HAART) is the preferred regimen while rifampicin (RIF) based anti-TB treatment regimen is a choice to 
treat TB-HIV co-infection in resource-limited settings. RIF is a known enzyme & drug transporter inducer and/or 
inhibitor. The dose of EFV to be used in the presence of RIF is, however, controversial. This thesis is primarily 
carried out to investigate the pharmacogenetic and pharmacokinetic aspect of drug-drug interaction between RIF & 
EFV aiming to optimize the dose of EFV to be used in TB-HIV co-infected Ethiopian patients. 
This study was designed to be carried out in two sub-Saharan African countries (Ethiopia and Tanzania), owning to 
the heterogeneity of the region genetically and culturally. This thesis focuses on the Ethiopian population. The thesis 
was conducted by prospectively recruiting cohort of HIV infected individuals without TB (Arm 1; N = 285) in 
parallel to another cohort of HIV co-infected with active TB (Arm 2; N = 196). All study participants were adults 
with baseline CD4 count less than 200 cells per mm3 and were followed for a year. At baseline and follow up periods, 
clinical chemistry (liver and kidney function tests), hematological parameters (complete and differential blood cell 
counts) and HAART outcome monitoring (CD4 counts and HIV RNA viral load) were done. In addition, genotyping 
for CYP2B6*6, CYP3A5 (*3, *6, *7), UGT2B7*2, NAT2, ABCB1 (3435 C > T & 3842 A > G) & SLCO1B1 (*1b & 
*5) were also done. Pharmacokinetic variables such as plasma/intracellular concentrations of EFV, 8-hydroxy-
efavirenz (major metabolite) & metabolic ratio were determined at weeks 4 and/or 16, 16±1h post-dose. Besides, 
cholesterol, 4β-hydroxy-cholesterol (biomarker for CYP3A activity) & metabolic ratio at weeks 0, 4, 16 & 48 were 
also determined to investigate time-dependent effect of EFV on CYP3A enzyme. Socio-demographic factors (Age, 
sex, baseline body weight and BMI) were also recorded.  
This thesis reports paradoxical increase in plasma/intracellular EFV concentrations by RIF co-therapy; coherent to 
this is improved immunological outcomes among individuals co-treated for TB and HIV with comparable virologic 
success to HAART than those without RIF co-treatment. The thesis also shows wide between-subject variability in 
the long-term auto-induction by EFV based on CYP2B6 genotype. Between & within-subject variability in plasma 
EFV concentration and immunological outcome are shown to be influenced by RIF co-therapy, CYP2B6 genotype 
and baseline body weight. Besides, the thesis demonstrates the influence of CYP2B6 genotype on CYP3A auto-
induction by EFV in a gene-dose dependent manner, CYP2B6 (*6/*6 > *1/*6 > *1/*1). Furthermore, the thesis 
reveals the importance of differences in ethnicity & environmental factors contributing to wide between-population 
variability in EFV auto-induction comparing Ethiopian & Tanzanian patients. In addition, associations of CYP2B6, 
ABCB1 (3842A >G), slow NAT2 metabolizing genotypes & plasma concentration of EFV with increased incidences 
of drug-induced liver injury (DILI) and correlation of plasma and intracellular concentrations of EFV are reported in 
the thesis. The thesis also shows the long-term but not short-term effects of sex and UGT2B7 genotype in predicting 
auto-induction as well as plasma concentration of EFV.  
In conclusion, EFV dose-escalation from 600mg to 800mg is not required during TB-HIV co-treatment in Ethiopian 
patients. CYP2B6*6 genotype is not only a strong predictor for EFV pharmacokinetics but also could predict EFV-
based HAART outcomes, DILI & CYP3A auto-induction by EFV. In addition to pharmacogenetic variability, the 
importance of differences in ethnicity & environmental factors are highlighted to optimize HIV treatment across sub-
Saharan Africa.   
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1. INTRODUCTION 
1.1. Common infectious diseases: an overview 
More than 1400 species of infectious agents have been reported to cause diseases in humans. 
These include pathogens for some 347 diseases of sustained clinical importance, according to 
the recent review by Hay et al [1]. Although caused by vastly different pathogens, the world’s 
three most serious infectious diseases are, tuberculosis (TB), malaria and human 
immunodeficiency virus (HIV) caused by mycobacteria, protozoa and retrovirus, respectively. 
Together, they cause ~5 million deaths per year and substantially affect the lives of a billion 
people world over [2]. Sub-Saharan African countries are hugely affected by these infectious 
diseases and the region harbors the highest burden of mortality and morbidity due to the 
diseases. Among these, TB and HIV are highly associated immuno-pathologically. Curable 
drug therapies are available for TB and malaria while HIV progression to AIDS could also be 
controlled by combination of antiretroviral drugs, although life-long administration of the drugs 
is required. There are immense challenges associated with the management and control of the 
diseases world over but worse in developing world due to expanding population, high disease 
burden and limited access to public health facilities.  
1.1.1. HIV epidemiology & current treatment: global, regional & national scenario  
Human immunodeficiency virus (HIV) is a chronic retroviral infection and a causative agent of 
acquired immunodeficiency syndrome (AIDS). The first case of HIV infection was identified 
in 1981 [3]. It has affected the lives of millions since and still continues to be one of the major 
leading cause of death [4-6] with cases virtually reported from every country. An estimated 34 
million people were globally living with the virus at the end of 2010 [7]. Furthermore, an 
estimated 2.7 million new HIV infections and 1.8 million deaths from AIDS-related illnesses 
were reported during the same year. Sub-Saharan Africa remains the region most heavily 
affected by the virus, accounting for 68% of people living with HIV and 70% of new infections 
in 2010 [7].  
Ethiopia is geographically located in the eastern horn of Africa. It is second most populous 
African country, with an estimated inhabitant for over 80 million people in 2008 [8].  Like 
most other sub-Saharan African countries, Ethiopia has experienced a severe HIV epidemic 
since the mid-1980s [9, 10] and HIV-1 infection was first documented in 1984 in Ethiopia [11]. 
Subsequently, the first clinically overt case of AIDS was diagnosed in 1986 [12]. The epidemic 
has expanded rapidly and reached a plateau around the mid-1990s and Ethiopia remained one 
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of the hardest hit countries by the epidemic with an estimated adult HIV prevalence rate of 
1.5% in 2011 [13].   
The introduction of highly active antiretroviral therapy (HAART) has substantially resulted in 
reductions of HIV-related morbidity and mortality globally [14-16] WHO 2010 [7]. Current 
WHO guidelines recommend use of a standard first-line regimen consisting of either two 
nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), efavirenz or nevirapine, or a triple NRTI regimen, and a 
second-line regimen consisting of a boosted Proteases inhibitor (PI) with at least one NRTI [7].  
The currently available antiretroviral drugs (ARV) are effective in suppressing viral replication 
and reduce the plasma viral load to the level below the detection limit, significantly restore the 
immune function and reducing HIV-associated morbidity and mortality [17-19].    
1.1.2. TB and HIV co-infection: epidemiology and co-treatment challenges 
Tuberculosis (TB) and HIV are interacting epidemic diseases. TB is the commonest 
opportunistic infection and leading cause of death among HIV infected individuals [20]. 
Likewise HIV complicates TB infection and is associated with a more rapid clinical decline. 
Infection with HIV increases the risk of reactivating latent TB infection and HIV-infected 
individuals who acquire new TB infections have high rates of disease progression [21, 22]. TB-
HIV co-infected individuals are at high risk of death [23, 24]. 
The lifetime risk of developing active TB in HIV uninfected individuals is approximately 10%; 
but the annual risk among HIV-infected patients is ~10%, while the lifetime risk approaches 
50% among them, as reviewed by Habib [25]. According to the recent WHO report [26], in 
2010, there were 8.8 (range, 8.5–9.2) million incident cases of TB, 1.1 (range, 0.9–1.2) million 
deaths from TB among HIV uninfected individuals and an additional 0.35 (range, 0.32–0.39) 
million deaths from HIV-associated TB globally. The highest rates of TB-HIV co-infection are 
in the African Region, where 44% of TB patients with an HIV test result were HIV infected 
(range among high TB-HIV burden countries, 8%–82%).    
Ethiopia is among the first 22 TB burden countries and also among the 41 high TB-HIV co-
infection burden countries [26]. As reviewed by Seyume and Legesse [27], during the year 
2011, a total of 159,017 TB cases and about 38,000 HIV-associated new TB cases were 
notified in Ethiopia. Among 65,140 TB patients who were screened for HIV infection, 5,442 
were found to be co-infected with HIV. The rate of TB and HIV co-infection is high in 
Ethiopia ranges from 25% to 57% in different regions of the country [28, 29]. 
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In co-infected patients, the priority is to treat TB with anti-tubercular (anti-TB) drugs before 
the initiation of highly active antiretroviral therapy (HAART) in anti-retroviral-naïve patients 
[30]. The anti-TB drugs used to treat drug-sensitive TB are universally the same, independent 
of HIV status although the thrice a week TB treatment regimen is recently disfavored by WHO 
among TB-HIV co-infected individuals due to higher rate of relapsing TB [26]. HAART 
reduces TB rates by up to 90% at an individual level, by 60% at a population level and reduces 
TB recurrence rates by 50% [31, 32], indicating the importance of initiating HAART for all 
people living with HIV and active TB disease, irrespective of CD4 cell count [26].  
However, TB-HIV co-treatment poses several management challenges [33]. The optimum time 
to initiate HAART in TB-HIV co-infected individuals remains unclear [34]. Among the three 
milestone studies, SAPIT (Starting Antiretroviral therapy at three Points In Tuberculosis 
therapy) of South Africa [35] and CAMELIA (Cambodian Early versus Late Introduction of 
Antiretroviral Drugs) of Cambodia [36] showed reduced incidence of all-cause mortality, hence 
improved survival when HAART was introduced simultaneous to anti-TB treatment in cohorts 
of TB-HIV co-infected patients. Even AIDS Clinical Trial Group (ACTG) study called 
STRIDE (Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults 
Being Treated for Tuberculosis), association of earlier HAART with a lower rate of new AIDS-
defining illnesses and death was reported among individuals with CD4 counts less than 50 cells 
per mm3 [37]. The above studies solidify the benefits of HAART introduction during anti-TB 
treatment. On the other hand, concurrent treatments of TB-HIV co-infection create several 
management challenges, including pharmacokinetic drug interactions, overlapping drug 
toxicities, TB immune reconstitution inflammatory syndrome (TB-IRIS) and high pill burden, 
which potentially affects adherence [38]. To minimize these risks, optimization of TB-HIV co-
treatment is of paramount importance either through selection of appropriate HAART regimens 
or optimized dosage.   
1.2. Antitubercular & anitretroviral drugs: challenges of concomitant use 
WHO recommends that the first-line HAART regimen contain two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor 
(NNRTI). The preferred NRTI backbone is zidovudine (AZT) or tenofovir disoproxil fumarate 
(TDF), combined with either lamivudine (3TC) or emtricitabine (FTC) [7]. By and large, 
NRTIs remain the backbone of HAART during TB-HIV co-treatment due to their safety, 
efficacy and favorable drug-drug interaction profiles, reviewed by Aaron [30]. However, 
potentially deleterious outcomes of simultaneous co-administrations of the anti-TB drugs with 
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NNRTIs are challenging due to pharmacokinetic drug – drug interactions (DDIs) and 
overlapping drug toxicities [33, 39]. 
1.2.1. Pharmacokinetic interactions: emphasis on rifampicin & efavirenz 
Drug interaction between current ARV and anti-TB drugs is a problem. The majorities of the 
clinically significant drug interactions are pharmacokinetic-based [40], mainly through 
cytochrome P450 (CYP450) enzyme induction or inhibition in the liver [30]. The isoform 
CYP3A4 is particularly important as it is the main enzyme responsible for the metabolism of 
PIs and to a lesser extent, NNRTIs [41, 42]. Amongst the potent inducers of CYP3A4 are the 
rifamycin family [43]. Rifampicin (RIF) is a cornerstone anti-TB drug. It is a potent inducer of 
many genes controlling drug metabolism and transport, including CYP3A4 and the drug efflux 
pump p-glycoprotein [44]. Induction of CYP3A4 may reduce plasma concentrations of 
concomitantly administered ARV drugs, potentially leading to inferior HAART outcomes [45, 
46]. Besides, increased activity of the drug transporter (P-glycoprotein) may affect the 
absorption, distribution and elimination of PI [47, 48].  
NRTIs are mostly metabolized by glucuronidation and are free of significant interactions with 
rifamycins, as reviewed by Schutz C [49]. Clinically significant interactions may occur 
between RIF and NNRTIs. Pharmacokinetic data showed that RIF reduced nevirapine (NVP) 
to sub-therapeutic concentration [46, 50]. Therefore, the data to date suggest that if RIF and an 
NNRTI are to be used then efavirenz (EFV) is preferred [7], although it is unclear whether this 
has any clinical impact. Besides, there is no agreement on the appropriate dose of EFV to be 
co-administered with RIF.  
Pharmacokinetic studies have found a 20–30% reduction in EFV plasma levels when co-
administered with RIF [51] and that increasing the dose of EFV from 600 mg to 800mg is 
effective and safe [51, 52]. Conversely cohort studies employed the standard 600mg dose of 
EFV with RIF but clinical efficacies were not compromised [53-55]. A large cohort study 
conducted in South Africa showed no difference in rates of virological suppression when 
comparing patients on EFV-containing HAART alone and those on EFV-containing HAART 
and RIF-based TB treatment concurrently. EFV was used at a dose of 600 mg irrespective of 
body-weight in this cohort [56].  
In contrast, an observational cohort, looking at body-weight stratified pharmacokinetic and 
clinical outcomes, suggested that for patients weighing 60kg, a dose of 800mg of EFV should 
be prescribed [50], although this was not observed in African patients [45]. A major problem is 
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large between-subject variability in EFV concentrations [57] and this is compounded by the 
fact that EFV levels and associated toxicity are increased in individuals with polymorphisms in 
CYP2B6, present in over 20% of the black population compared with 3% of whites [58, 59]. 
This may explain some of the variability and high rates of clinical toxicity in some studies [60]. 
Drug-gene interactions studies were also recommended [61]. Based on available data, standard 
doses of EFV can be given to patients weighing 60kg, but in patients weighing 60kg an 
increase to 800mg can be considered [33, 47].   
1.2.2. Overlapping toxicities: emphasis on drug induced liver injury (DILI) 
HIV infection per se results in an increased rate of serious adverse events in patients on TB 
treatment [62]. In addition, shared toxicities with anti-TB and ARV drugs are common: rash, 
fever, peripheral neuropathy and drug-induced liver injury (DILI) being highly common 
adverse effects [30, 49]. Amongst which, DILI is the most commonly shared toxicity by anti-
TB drugs and NNRTIs and PIs. Close monitoring of liver functions are required. Severe DILI 
was found in 7.7 per 100 person-years in an African cohort; although in TB-HIV co-infected 
patients, treatment of TB increased its risk by 8.5-fold [63].  
Among the first-line anti-TB drugs pyrazinamide, isoniazid and RIF have all been associated 
with DILI [64]. There are concerns about increased incidence of DILI when NNRTIs are 
concomitantly used with the anti-TB drugs. Increased propensity of DILI was seen when both 
EFV [65, 66] and NVP [66] were administered concomitantly with TB treatment. Boosted PIs 
with RIF-based TB treatment may also result in DILI [67-69]. Development of deranged liver 
functions may significantly complicate treatment of co-infected patients [70].  
1.3. Pharmacogenetics 
Individuals differ in response to administration of equal dose of a drug. Various factors have 
been described to contribute between-subject variability in drug response; amongst those 
factors, the contribution genetic variability has received much focus. Pharmacogenetic is a 
scientific discipline that deals with the identification and description of genetic diversity to 
ascribe differences in drug response through candidate-gene approach. The related discipline 
often confused with pharmacogenetics is pharmacogenomics which uses whole human genome 
to explain between-subject variability in drug response through genome-wide association 
studies (GWAS).  
Mutational changes on certain candidate-genes affect pharmacokinetics processes, mainly drug 
metabolism and transmembrane drug transport processes. Identification of single-nucleotide 
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polymorphisms (SNPs) on genes affecting these processes significantly impact inter-individual 
and inter-population variability on drug exposure parameters, which, in turn, may influence 
drug responses at both individual and population level, respectively [71].  
1.3.1. Pharmacogenetics of drug metabolizing enzymes 
Approximately all systemically absorbed drugs undergo biotransformations mediated by 
mainly hepatic and rarely extrahepatic enzymes through phases I and II. Phase I 
biotransformation involves mainly oxidation reactions mediated by hepatic and extrahepatic 
enzyme systems called Cytochrome P450 (CYP450) and Phase II metabolism involves 
conjugation reactions mainly glucouridation by UGT enzyme system.  
1.3.1.1. Cytochrome P450 (CYP450) enzymes 
The most important eliminating pathways for lipophilic drugs are CYP450 dependent oxidation 
to polar metabolites. Mo et al [72] reviewed that the human hepatic CYP system consist of 
over 30 related isoenzymes with different, sometimes overlapping substrate specificities. The 
enzymes belonging to the families CYP1, CYP2 and CYP3 catalyse biotransformations of 
xenobiotics including 90% of clinically used drugs [73, 74]. Mutant alleles carrying certain 
nucleotide substitutions, deletions or insertions result in abnormal activity and variability in the 
contents of the CYP [74]. This, in turn, leads to between-subject variability of CYP metabolic 
rates [75]. Evidences exist that difference in CYP enzymes metabolic capacities leading to 
inter-individual variability in therapeutic responses of drugs [76-78]. Most CYPs are subject to 
enzyme induction and inhibition, leading to DDIs. Clinically significant DDIs between anti-TB 
and ARV drugs have been explained through inductions at CYP2B6 and CYP3A enzyme 
systems [79, 80].  
1.3.1.1.1. CYP2B6  
The human CYP2 cluster is located on chromosome 19q 13.2. This cluster contains the loci for 
six functional genes including CYP2A6 and CYP2B6 subfamilies [81]. CYP2B6 is mainly 
expressed in liver, accounting for 6% of the total microsomal CYPs as reviewed by Mo et al 
[72]. Although, this enzyme was historically thought to play insignificant role in drug 
metabolism, the discovery of genetic polymorphisms and inter-ethnic differences in CYP2B6 
expression [82, 83], identification of additional substrate drugs [72] as well as evidences of its 
co-regulation with CYP3A [84-86] stimulated renewed interest.  Currently, CYP2B6 enzyme is 
known to metabolize ~8 - 10% of drugs including chemotherapeutics, opioids and ARV drugs 
such as NVP and EFV [87].  
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Certain SNPs at CYP2B6 gene have been associated with high between-subject variations on 
substrate drugs exposure. Four exonic SNPs, 516G > T, 714G > A, 785A > G and 983T > C 
were identified [88]. The relative importance of each of the SNP varies among different races 
and ethnicity. Worldwide, inter-population diversity in CYP2B6 516G>T allele frequency 
ranges between 25 to 69% [89]. CYP2B6 516G>T SNP is abundant among black Africans 
[90]. The inter-population variability in the allele frequency of mutated CYP2B6 516G>T SNP 
was reported to vary between 20 to 50% among Africans, suggesting ethnic differences in the 
expression of the enzyme within the same race [91].  
The identification of CYP2B6 enzyme as the major metabolic pathways for the first-line ARV 
drugs, such as NVP and EFV [92], has also stimulated renewed interest. Differences in NVP 
and EFV exposures were reported, owing to the existence of between-subject variability due to 
differences in the expression of CYP2B6 at individual level [45, 93]. Individuals with non-
functional (mutated) CYP2B6 gene showed higher drug exposures, possibly leading to higher 
incidences of toxicities [72]. Evidences for CYP2B6 inducibility by RIF [85], its auto-
inducibility by EFV and NVP [94] and inhibition by certain drugs, have led to investigations to 
identify clinically relevant drug - drug interactions. Moreover, the intracellular co-regulation 
similarities of CYP2B6 and CYP3A enzymes have also been the basis for DDI studies [84-86].   
CYP2B6 is induced by a large number of compounds with diverse structures, as reviewed by 
Tompkins [95]. Constitutively active receptor (CAR) is a nuclear receptor containing 
functional domains, including a DNA-binding domain and a ligand-binding domain. CAR was 
shown to have much smaller ligand-binding domain than PXR. In addition, unique structural 
conformations were identified that may explain CAR’s ligand independent activities [96]. The 
induction of CYP2B family is activation. Along with CYP2B induction, up-regulation of other 
genes including CYP2C, CYP3A, glucuronosyltransferases and transporters occurs with CAR 
activation [97].  
1.3.1.1.2. CYP3A 
The CYP3A iso-enzymes constitute the largest portion of CYP450 protein in the liver and 
small intestine [98-100] and are located adjacent to each other on chromosome 7q21. The 
CYP3A family is composed of four enzymes: CYP3A4 (the major isoform), CYP3A5, 
CYP3A43 and CYP3A7. Among these, CYP3A4 and CYP3A5 account for the majority of the 
catalytic activity of the enzyme subfamilies [91, 101]. They are responsible for the metabolism 
of 50–60% of all currently available drugs as well as endogenous substances such as 
cholesterol and steroidal hormones. 4β-hydroxy-cholesterol (4β-OHC) is metabolic product of 
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cholesterol via CYP3A. Its plasma level was shown to be an endogenous biomarker for 
CYP3A enzyme activity [102, 103]. However, in cases where plasma cholesterol levels are 
expected to vary, 4β-OHC to Cholesterol (4β-OHC/Chol) ratio was suggested to be used as 
marker for the enzyme [104].  
Multiple nuclear receptor binding sites control both the basal and inducible expression of 
CYP3A and ensure sensitivity to a number of structurally diverse substrates [105]. Expressions 
of CYP3A enzymes involve the nuclear hormone receptors pregnane X receptor (PXR) and 
retinoid X receptor (RXR) [106]. Substantial inter-individual differences in CYP3A enzyme 
expression contribute to variation in oral bioavailability and systemic clearance of CYP3A 
substrates. Not only the expression but also the induction of CYP3A shows large inter-
individual variations [95]. Among many, rifampicin (RIF) and efavirenz (EFV) are known to 
induce [107] while most PIs inhibit CYP3A activity [108, 109].  
The contribution of CYP3A5 to drug metabolism was shown to vary from 6 to 99% of the total 
CYP3A activity in different populations [101, 110]. CYP3A5 is reported in detectable amounts 
in only 10 to 30% of adult white people and Asians, whereas 60% of African Americans 
express the protein [110], wide intra-continental variation in the expression of CYP3A5 
enzyme has been reported within African continent [111].These variations may be due to the 
modulation of CYP3A expression through a wide array of environmental factors, drug-drug 
interactions and genetic variations. CYP3A5 is polymorphic and displays inter-individual and 
interracial differences in expression and CYP3A-dependent drug clearance and responses 
hence may be an important genetic contributor [112]. The main reason for variability of 
CYP3A5 activity is SNPs at 27289C<A, 6986 A<G, G14690A and 27131-32insT yielding 
prematurely truncated and thus non-functional enzymes namely CYP3A5*2, CYP3A5*3, 
CYP3A5*6 and CYP3A*7 variants, respectively [110]. Individuals carrying at least one 
CYP3A5*1 allele can express high levels of CYP3A5 enzyme.  
1.3.1.2. Conjugating enzymes: emphasis on UGTs and NATs 
Phase II enzymes conjugates phase I metabolites or parent drugs for renal and biliary 
excretions. Phase II enzymes include glutathione-S-transferase  (GST), Thiopurine-S-
methyltransferase (TPMT), UDP-glucuronosyl transferases (UGTs), N-acetyltransferases 
(NATs) and others. UGTs are the major conjugation drug biotransformation pathway while 
inter-individual and inter-population variability due to polymorphisms on NATs has been 
identified early.  
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The UGTs are distributed in many tissues including liver, small intestine, kidney, colon and 
brain [113]. UGTs mediate metabolisms of various endogenous substrates such as bile and 
steroid hormones as well as chemically diverse xenobiotics, as reviewed by Lin and Wang 
[114]. A great deal of drugs from almost all therapeutic classes including ARV drugs such as 
zidovudine (NRTI) and efavirenz (NNRTI) undergo glucuronidation [115]. Similar to some 
CYP450 enzymes, the expressions of UGTs is inducible and the mechanism of their cellular 
regulation was suggested to be similar as that of CYPs through activations of PXR and CAR 
nuclear receptors, reviewed by Zhou et al [116]. In addition, Zhou et al described other nuclear 
receptors which regulate transcriptions of UGTs such as farnesoid X receptors (FXR), 
peroxisome proliferator activated receptors (PPARƔ) and glucocorticoid receptor (GR). Many 
classical CYP450 inducers including RIF and phenobarbital were shown to induce UGTs in 
vitro and in animal studies [117, 118]. A number of UGT isoforms have been identified in 
human, encoded either by UGT1A or UGT2B gene subfamilies. UGT2B7 enzyme system is 
the major UGT isoform, highly polymorphic and is involved in the metabolism of ARV drugs 
like zidovudine and efavirenz [89, 115, 119]. 
N-acetyltransferases (NATs) are involved in the metabolism of drugs and environmental 
toxins. They catalyze the acetyltransfer from acetyl-coenzyme A. Sequence variations in the 
human NAT1 and NAT2 result in the production of NAT proteins with variable enzyme 
activity or stability, leading to slow or rapid acetylation [120, 121]. Genetic polymorphisms in 
NAT1 and NAT2 have been associated with drug-induced toxicities and disease, according to 
the reviews [122-124]. NAT1 and NAT2 occur in the liver, with NAT2 being 2 to 10 times the 
level of NAT1, depending on the NAT2 status of slow or rapid acetylator, respectively [125]. 
There are two distinct phenotypes for NAT2: ‘fast’ and ‘slow’ acetylators, measured in vivo 
using substrates such as isoniazid, dapsone and caffeine. The slow isoform of NAT2 is present 
in up to 90% of some Arab populations, in 40–60% of Caucasians and Indians and in 5–25% of 
East Asians [126-128]. Genetic polymorphism of the NAT2 is strongly implicated in 
differential susceptibility to adverse drug reactions [122, 129].  
The NAT2 acetylation polymorphism was discovered over fifty years ago when individual 
variability in isoniazid (INH) neurotoxicity was attributed to genetic variability in N-
acetylation [130]. Among the first-line therapeutic drugs for TB, INH is the drug principally 
associated with drug-induced hepatotoxicity [131]. In the liver, INH is first metabolized into 
acetylisoniazid via NAT2 [132] followed by hydrolysis to acetylhydrazine, subsequently 
acetylhydrazine is oxidised into hepatotoxic intermediates [133, 134].  
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1.3.2. Pharmacogenetics of drug transporter proteins 
A drug molecule passes through several biological membranes during pharmacokinetic 
processes. The extent of transmembrane movement of drugs is affected by the physicochemical 
properties of a drug. In addition, membrane transporters have a significant role in facilitating or 
preventing drug movement. Drug transporters may be either influx (uptake into cell) or efflux 
(out of cell) transporters, which are typically located either at the basolateral or apical 
membrane in polarized cells, reviewed by Kalliokoski et al [135]. The level of expressions and 
functionalities of membrane transporters are critical modulators for pharmacokinetic processes 
[136].  
1.3.2.1. Efflux transporters: ABCB1 
Efflux transporters are involved in energy-dependent efflux pump of xenobiotics from inside to 
outside via the plasma membrane. The most widely known efflux transporter proteins, p-
glycoproteins (P-gps) are transmembrane proteins present in intestinal epithelial cells, biliary 
canalicular cells, blood-brain barrier, lymphocytes and on the luminal surface of proximal 
tubule kidney cells, hence virtually affecting all pharmacokinetic processes [137]. Evidences 
show that a large group of drugs, including ARV drugs like most PIs were shown as substrates 
to this efflux transporter protein [138]. 
Multidrug resistance 1 gene (MDR1), also called ATP-binding cassette transporter (ABCB1), 
codes for P-gps. Several SNPs have been described on ABCB1 gene, the SNP 3435C >T, 
located in exon, has been shown to be associated with lower intestinal P-gp expression and 
activity in vivo [139-141]. Individuals homozygous for the mutation at position 3435 (TT) had 
significantly lower P-gp expression in the small intestine compared to those with functional 
variants and showed the highest plasma concentrations of some drugs after oral administration 
[139-141]. Pronounced ethnic difference in the alleles distribution of ABCB1 gene was also 
described [142-144]. The cellular expression of ABCB1 gene could either be induced or 
inhibited.  
1.3.2.2. Influx transporters: SLCO1B1 
Contrary to efflux system, influx transporters are ATP-independent pumps, importing 
xenobiotics from outside to inside across cellular transmembrane [135]. They are either organic 
cationic transporter peptides (OCTPs) or anionic transporter peptides (OATPs) [145].OATPs 
are expressed in a wide variety of tissues including liver, kidney, brain and small intestine 
[146]. A number of human OATP families have been identified, of those the roles of 
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OATP1B1, OATP1A2, OATP1B3 and OATP2B1 were characterized in drug pharmacokinetics 
[146].   
OATPs are encoded by genes of the solute carrier organic anion transporter (SLCO) family. 
The genes encoding human OATP1 family members are located in chromosome 12. Articles 
have reviewed the pharmacogenomics of OATPs and the role of OATP1B1 in drug elimination 
[135, 136, 147]. According to the reviews, numerous SNPs had been identified in SLCO genes 
[148,149]. These polymorphisms may lead to significant consequences on drug 
pharmacokinetics.  
OATP1B1 is mainly expressed on the sinusoidal membrane of human hepatocytes, also 
possibly in the small intestinal enterocytes [150, 151]. Substrates of OATP1B1 include a large 
number of structurally diverse drugs including statins, rifampicin and many others. Rifampicin 
was shown to be both inhibitor and inducer of OATP1B1 in vitro [152, 153].  In addition, some 
PIs were identified as inhibitors for OATP1B1 [154-156]. According to the review by Niemi 
[147], a large number of SNPs and other sequence variations have been described in the gene 
region of SLCO1B1 [149]. Of the variants identified, 521T>C SNP has been associated with a 
markedly reduced transport activity in vitro using several OATP1B1 substrates, including 
rifampicin. The 521T>C variant is common in non-African populations, with the variant allele 
frequency ranging between 10 and 20%. Another common variant associated with altered 
transport activity in vitro is 388A>G SNP [147, 157].  
1.3.3. Pharmacogenetics of efavirenz 
Efavirenz (EFV) displays nearly complete absorption from the gut and the Cmax reaches up to 
5h after oral administration. It is highly bound (over 99%) to plasma proteins, mainly to 
albumin. It is also widely distributed in different body fluids. Elimination of EFV is through 
both oxidation and conjugation by CYP450 and UGT enzyme systems, respectively, to its 
inactive metabolites and excreted mainly in urine.  
Efavirenz (EFV) undergoes complex metabolic processes. It is metabolized mainly to 8-
hydroxy-efavirenz (8-OH-EFV), primarily by CYP2B6 to a lesser extent by CYP3A4/5 [158, 
159]. These enzymes are genetically polymorphic. Polymorphisms at 516G>T (Q172H) and 
785 A>G (K262R) have been associated with pronounced decreases in CYP2B6 expression 
and activity as well as low rate of EFV hydroxylation [160]. CYP3A5 polymorphisms per se 
did not seem to affect EFV exposures significantly as its role in 8-hydroxylation of EFV is 
minimal. However, among individuals with non-functional genotypes for CYP2B6, the role of 
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CYP3A5 polymorphism may be important. Besides, EFV is also metabolized to 7-hydroxy-
efavirenz (7-OH-EFV) by CYP2A6 [158] and evidences showed that EFV also undergoes 
direct glucuronidation by UGT2B7 to efavirenz-N-glucuridine [115]. UGT2B7 was also shown 
to be polymorphic, although evidences lack the influence of the polymorphism in relation to 
EFV exposure among individuals with distinct CYP2B6 genotypes [161]. The major metabolite 
of EFV, 8-OH-EFV, also undergoes secondary hydroxylation to 8,14-dihydroxy-efavirenz 
again by CYP2B6 and glucuronidation to 8-hydroxy-glucuridine by UGT2B7 enzyme [162-
164].  
Attempts to investigate transmembrane transport of EFV and pharmacogenetics of drug 
transporter proteins on EFV are a few. No conclusive report exists whether EFV is substrate to 
MDR1 transporters as previous reports are conflicting [165-168]. Moreover, reports are a few 
whether EFV is a substrate or inducer/inhibitor of influx transporter proteins, mainly OATPs, 
except that Janneh et al [167] suggested that intracellular accumulation of EFV may be due to 
interaction with SLCO3A1 while Weiss et al [169] showed that EFV up-regulated expressions 
of SLCO3A1and SLCO2B1 in vitro.  
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2. THIS THESIS 
2.1. Rationale of the thesis 
The current WHO guideline for treatment of HIV recommends the use of efavirenz-based 
HAART as the preferred first-line regimen in the presence and absence of TB co-infection, 
complying with this are most sub-Saharan African countries including Ethiopia. The fact that 
appreciable proportion of HIV infected individuals also develops TB in Ethiopia, by and large; 
co-treatment of TB with rifampicin-based anti-TB drugs and HIV with EFV-based HAART is 
inevitable. Owing to enzyme induction by RIF, plasma exposure of EFV is described to reduce, 
as a consequence, may lead to HAART failure.  
There is no agreement on the appropriate dose of EFV to administer with RIF. This thesis 
primarily investigated whether EFV dose escalation is necessary or not when co-treating HIV 
in TB and HIV co-infected Ethiopian patients receiving RIF-based anti-TB treatment. Earlier 
studies conducted on Caucasians showed 20–30% reduction in EFV levels when administered 
with RIF, recommending dose increment of EFV from 600 mg to 800mg. Conversely, recent 
cohort studies in non-Caucasian populations showed that when standard dose of EFV (600mg) 
was given with RIF, clinical efficacy of HAART was not compromised. Current 
recommendations suggest that when EFV is to be used concomitantly with RIF, the standard 
dose of EFV (600mg) to be used or to be adjusted upward to 800mg based on the body-weight. 
Even then, there is no agreement in the body-weight cut-offs.  
The existence of extensive heterogeneity in relation to genetic diversity, environmental 
exposures and dietary habits coupled with pharmacogenetically under explored facts among 
populations in sub-Saharan African countries also stimulated this thesis. The fact that Ethiopia 
is the 2nd highly populous country in Africa, and one of the worst affected countries by HIV 
and TB burden, the distinct genetic make-up and dietary habits of the population in Ethiopia as 
opposed to other sub-Saharan African countries had been another impetus for the design of this 
study to be conducted parallel in two sub-Saharan African countries, namely Ethiopia and 
Tanzania.   
Given the genetic heterogeneity of sub-Saharan African population, wide inter-population 
differences in the distribution of allele frequencies of EFV metabolizing enzymes and 
transporter proteins are expected. This thesis also describes the pharmacogenetics of EFV and 
investigates the effects of long-term administration of EFV on its pharmacokinetics and linking 
this to treatment outcomes in Ethiopian HIV patients. The thesis also attempts to characterize 
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the influences of pharmacogenetic factors, demographic variables, biochemical lab parameters 
and hepatitis B and C co-infections on pharmacokinetics and pharmacodynamic of EFV in 
Ethiopian TB and HIV co-infected patients. This thesis also investigated the link between 
pharmacogenetic based pharmacokinetic differences resulting drug-induced liver injury (DILI) 
among TB and HIV co-treated Ethiopian patients. In addition, the thesis characterized the 
factors affecting EFV pharmacokinetics and pharmacodynamic differences in HIV patients 
based on ethnic differences by comparing these from two sub-Saharan African countries, 
namely Ethiopia and Tanzania.     
2.2. Objectives 
2.2.1. General objective 
To investigate the pharmacokinetic and pharmacogenetic aspects of drug – drug 
interactions aiming to optimize efavirenz dose to be co-administered with rifampicin in 
Ethiopian patients. 
2.2.2. Specific objectives 
1. To investigate impacts of long-term auto-induction by efavirenz and pharmacogenetic 
factors on plasma/intracellular drug exposure and immunologic outcome over time. 
2. To assess pharmacogenetic and pharmacokinetic influences of efavirenz on CYP3A 
induction over time using 4β-hydroxy-cholesterol metabolic ratio as biomarker. 
3. To characterize impacts of ethnicity and pharmacogenetic factors on pharmacokinetics 
of efavirenz and immunologic outcomes in two sub-Saharan African countries.  
4. To assess effects of efavirenz pharmacokinetic and pharmacogenetic factors on drug-
induced liver injury (DILI). 
5. To investigate influence of rifampicin co-therapy on plasma/intracellular efavirenz 
pharmacokinetics and immunologic and virologic outcomes of HAART. 
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3. METHODS 
3.1. Study design 
The study was designed to be conducted in two different African countries, namely Ethiopia 
and Tanzania and similar protocol has been employed to conduct the trial. This thesis focused 
mainly on Ethiopia as one of the two participating countries. The study was an open-label, 
parallel design consisting of cohorts of two arms followed prospectively for a year. HIV 
infected adults without active TB at the time of enrolment, naïve for HAART with absolute 
CD4 count less than 200 cells per mm3, hereafter called Arm 1 (Papers I, II & III), while HIV 
co-infected with active TB, naïve for both HAART and anti-TB regimens, hereafter called Arm 
2 (Papers IV & V).  
3.2. Study sites and population 
This study was primarily conducted by the Departments of Pharmacology and Internal 
Medicine, School of Medicine, Addis Ababa University (Ethiopia). Study subject enrolments 
and follow ups were conducted at HIV and TB clinics, which ran separately at the start of this 
study. The study sites were one tertiary level referral teaching hospital (Tikur Anbessa General 
Specialized Hospital) and six other health centers (Arada, Beletshachew, Bole, Kazan’chiz, 
Lideta and Meshua’lekia) in Addis Ababa. The capital city of Ethiopia is Addis Ababa, the 
inhabitant of most nations and nationalities of Ethiopia as well as people of varied socio-
economic status. This ensured the heterogeneity of the study population as a representative of 
Ethiopia.   
3.3. Recruitment of study participates  
As per the then national guideline, serologically diagnosed and confirmed HIV infected 
individuals with CD4 counts less than 200 cells per mm3 were eligible for HAART initiation. 
At HIV clinics, those HAART eligible HIV infected patients without active TB (Arm 1; 
N=285) were recruited (Papers I – V). Similar recruitment procedure was employed by TB 
clinics to recruit TB and HIV co-infected individuals (Arm 2; N=196) (Papers IV and V). TB 
diagnosis in Arm 2 patients was done either by microbiological, radiographical, clinical or 
combination of any of these. The inclusion criteria to participate in the study in both Arms 
were, age greater than or equal to 18 years, able to give written consent, who were not on any 
medication known to interact with the study drugs and did not have any significant 
hematological, liver and/or renal impairments at baseline (Papers I – V).  
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3.4. Treatments, clinical and laboratory monitoring 
Treatment of TB in TB-HIV co-infected individuals (Arm 2) was employed by a combination 
of body-weight adjusted dose of rifampicin (RIF) plus INH plus ethambutol plus pyrazinamide 
for 8 weeks (intensive phase) which was followed by 16 weeks of daily dose of RIF plus INH 
(continuation phase). TB treatment was done all through DOTs (Papers IV and V). While all 
recruited patients (both Arms 1 and 2) received combination of the first-line highly active 
antiretroviral therapy (HAART) consisting of 600mg daily dose of efavirenz (EFV) with 
zidovudine plus lamuvidine (AZT+3TC) or stavudine plus lamuvidine (d4T+3TC) or tenofovir 
plus lamuvidine (TDF+3TC) (Papers I – V). The EFV-based HAART was initiated on the 4th 
week of starting RIF-based anti-TB therapy in TB and HIV co-infected patients (Arm 2).   
At baseline and scheduled follow-up periods, all recruited patients had clinical examinations 
consisting of physical diagnoses and clinical laboratory measurements such as liver function 
tests (ALT, AST, ALP, total and direct bilirubin), renal function test (serum creatinine), 
hematological parameters (complete and differential blood counts, hemoglobin, hematocrit and 
albumin), the presence or absence of viral hepatitis co-infections (such as Hepatitis B surface 
antigen and Hepatitis C viruses), immunological parameter (CD4 count) and HIV-RNA viral 
load (Papers I – V).   
3.5. HIV treatment outcome and DILI monitoring 
HIV treatment response was mainly evaluated by change in absolute CD4 count (Papers I, II, 
III & V) and undetectable (< 50 copies per mL) HIV-RNA viral load (Paper V) at weeks 12, 
24 and 48 from the baseline value. Drug induced liver injury (DILI) monitoring was done at 
weeks 1, 2, 4, 8, 12, 24, 48 and 52 weeks after starting anti-TB therapy in Arm 2 while at 
weeks 1, 2, 4, 8, 12, 24, and 48 weeks after starting HAART in Arm 1. Liver biochemical 
parameters more than two times the upper normal limit (UNL) value were considered as DILI. 
Those greater than or equal to 5 times the UNL or equal to threefold elevation in ALT and 
simultaneous elevation of total bilirubin concentration greater than or equal to 2 times UNL 
were considered as severe DILI (Paper IV).  
3.6. Pharmacokinetic and pharmacogenetic specimen collection, isolation, 
storage and transport  
Specimens intended for pharmacokinetic and pharmacogenetic studies, treatment outcome 
monitoring and routine laboratory measurements were collected from brachial veins. To 
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determine plasma and intracellular concentrations of efavirenz (EFV) and 8-hydroxy-efavirenz 
(8-OH-EFV), duplicate blood samples (~8mL each) were collected 16±1h post-dose of 
efavirenz into CPT vacutainers (Becton Dickinson), at least once or at most twice on either 
week 4 or 16 or both, after start of HAART (Papers I – V). Standard operating procedures 
(SOPs) for isolations of the specimens from whole blood were described by Burhenne et al 
[166] and subsequently in Papers I and II.  The specimens were stored in -800C until transport 
in dry-ice pack to the Divisions of Clinical Pharmacology and Clinical Chemistry, Karolinska 
Institutet, Stockholm (Sweden) for genotyping analysis and determination of cholesterol and 
4β-OHC, respectively (Papers I - V). Specimens for quantifications of efavirenz (EFV) and 8-
hydroxyefavirenz (8-OH-EFV) were similarly stored and transported to the Division of Clinical 
Pharmacology and Pharmacoepidemiology, University of Heidelberg (Germany) for analysis 
(Papers I – V). 
3.7. Quantifications of pharmacokinetics indexes 
3.7.1. Efavirenz and 8-hydroxy-efavirenz by LC/MS/MS  
Plasma and intracellular EFV and 8-OH-EFV concentrations were determined by liquid 
chromatography–tandem mass spectrometry (LC/MS/MS). In brief, protein precipitation with 
ice-cold acetonitrile containing the deuterated and 13C-labelled internal standards was used for 
sample preparation and extraction. Extracts underwent chromatography on a Phenomenex® 
Synergi Fusion RP column with an eluent consisting of acidified 5mM ammonium acetate 
buffer, acetonitrile and methanol. Efavirenz and 8-hydroxyefavirenz were quantified using 
13C6-efavirenz and 2H4-8-hydroxyefavirenz as internal standards and electrospray tandem mass 
spectrometry in the selected reaction monitoring mode. The lower limits of quantification in 
plasma were 10.0 ng/mL for efavirenz and 0.4 ng/mL for 8-hydroxyefavirenz. The efavirenz 
(8-hydroxyefavirenz) calibration range was 10–10000 ng/mL (0.4–400 ng/mL). Linear 
regression with 1/X weighting resulted in correlation coefficients of r2>0.99. The accuracy and 
precision (intrabatch and interbatch) of the assay fulfilled all the recommendations of the FDA 
guidelines. Quality control results for accuracy and precision were in the range accepted by the 
FDA guidelines. 
3.7.2. Cholesterol and 4β-hydroxy-cholesterol  
Cholesterol concentrations were measured by a commercial enzymatic method (Cholesterol 
CHOD-PAPP, Roche Diagnostics GmbH, Mannheim, Germany) run on a Roche/Hitatchi 
Modular instrument. The between-day variation was 1.3% (at 5 mmol l-1). The determination 
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of 4β-hydroxy-cholesterol (4β-OHC) was performed by isotope-dilution gas chromatography–
mass spectrometry using deuterium-labeled 4β-OHC as an internal standard as described 
previously and modified by Diczfalusy et al [170]. The relative between-day variation (CV) 
was 4.9% (at 26.5 ng ml-1) (Paper II).  
3.8. Genotyping  
Genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA Maxi Kit 
(QIAGEN GmbH. Hilden. Germany). Genotyping was carried out at the Division of Clinical 
Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, 
Karolinska Institutet, Stockholm (Sweden). The SOPs for genotyping analysis were described 
in Papers I – V.  
3.9. Data collection, management and analysis 
3.9.1. Data collection and management  
Standard case report form (CRF) database was designed in MS Access. Both hard and soft 
copies of the database were employed to capture the study participants’ socio-demographic, 
pharmacogenetic parameters, baseline and follow-up laboratory values (pharmacokinetic 
parameters, biochemical, hematological, immunological and virological values). Besides, 
detailed baseline and scheduled follow-up clinical parameters including past medical history, 
physical diagnosis, karnofisky score, concomitant disease state (if any), concomitant use of any 
medication and assessment of self-reporting adherence. 
The data were collected by Good Clinical Practice (GCP) certified physicians, clinical nurses 
and lab technicians at real-time on the hardcopy of the CRF for each study participant then the 
same was entered by two independent data encoders. The double-entry was cross-checked by 
an independent data-manager periodically. Data cleanings were done before and after 
extraction of the data in MS excel spreadsheet format in preparation of transcription into 
relevant statistical software. 
3.9.2. Statistical analyses  
Normal distribution of the data was diagnosed by either Shapiro–Wilk or Kolmogorov–
Smirnov test or visual diagnostic checks before statistical analyses (Papers I - V). When 
abnormal distribution was diagnosed, the data were transformed to log to base 10. Independent 
t-test or Mann-Whitney U test and chi-square tests were used to compare independent groups 
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of continuous and categorical variables, respectively (Papers I – V). Kruskal–Wallis analysis 
of variance (ANOVA) was used for multiple comparisons (Papers I & II). Wilcoxon matched 
paired test was used to evaluate within-subject comparisons (Papers I, II III & V). Repeated 
measure and Freidman two-way ANOVA were used to investigate the influence of certain 
factors on change over time (Papers I, II, III & V). 
Univariate regression analysis was used to identify potential predictors and multiple linear 
regression analysis was employed to build the final models (Papers III, IV & V). Logistic 
regression was used to identify factors predicting virologic response, defined as non-detectable 
HIV RNA viral load < 50 copies/mL, (Paper V). Nonlinear mixed effect model and stepwise 
covariate model building were implemented (Paper III). Pearson and Spearman correlation 
analyses were also used (Papers I & II). 
Statistical analyses were performed using either IBM SPSS versions 15, 19 and 20 (Papers I – 
V) for Windows (IL, USA), Statistica version 10 (StatSoft Inc., Tulsa, OK, USA), NonMem 
Version 7.2 and PsN 3.5.3.or combinations of the above softwares (Paper III). GraphPad 
Prism 5 was used for graphical presentation of the data (Papers I – V). P values ≤ 0.05 were 
considered as significant.  
3.10. Ethical considerations 
The study had obtained ethical approvals by Institutional Review Boards of the Faculty of 
Medicine, Addis Ababa University (Ethiopia) and Karolinska Institutet (Sweden). Ethical 
approval was also obtained from Addis Ababa City Administration Health Bureau and National 
Health Ethics Committee at Ministry of Science and Technology. Drug Administration and 
Control Authority of Ethiopia granted final approvals to conduct the clinical study. Written 
informed consent was obtained from all study participants upon recruitment. The study was 
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4. RESULTS 
4.1. Impacts of efavirenz long-term auto-induction and pharmacogenetic 
factors on plasma/intracellular drug exposure and immunologic outcome. 
(Paper I) 
4.1.1. Effect of pharmacogenetic variation and sex on between and within subject 
variability of plasma and intracellular efavirenz pharmacokinetics 
The allele frequencies of CYP2B6*6, CYP3A5*3, CYP3A5*6, ABCB1 3435C_T and 
UGT2B7*2 (2327G_A, rs7662029) were 29.7%, 66.9%, 10.6%, 20.9% and 48.1%, 
respectively. There was no significant difference between the observed and expected genotype 
frequencies according to the Hardy–Weinberg equilibrium.  
Wilcoxon matched paired tests were used to compare within-subject variability (weeks 4 and 
16) for the median plasma and intracellular concentrations of EFV, 8-OH-EFV and EFV MR. 
No between-occasion variability was observed in both plasma and intracellular concentrations 
of EFV. However, significant differences in plasma 8-OH-EFV concentrations, with the 
corresponding decreases in EFV MR, were shown between weeks 4 and 16.  
Kruskal–Wallis ANOVA was employed to see the effects CYP2B6, CYP3A5, UGT2B7 and 
ABCB1 genotypes on plasma and intracellular concentrations of EFV, 8-OH-EFV and EFV 
MR of between-subject variability at each occasion (either at week 4 or 16). CYP2B6 genotype 
showed significant influence in both plasma and intracellular concentrations of EFV, 8-OH-
EFV and EFV MR at week 4. In addition, CYP2B6 genotype maintained significant influence 
on plasma concentrations of EFV at week 16. Controlling for the effect of CYP2B6 genotype, 
significant change over time (within-subject variability) in plasma concentrations of increased 
8-OH-EFV and decreased EFV MR among *1/*1 and *1/*6 genotypes but not among *6/*6. 
Similarly, intracellular concentrations of EFV and EFV MR showed significant difference over 
time, where in intracellular EFV MR decreased in *1/*1 and *1/*6 genotypes but increased in 
*6/*6 genotype. 
UGT2B7 genotype significantly affected plasma concentrations of 8-OH-EFV and EFV MR in 
long-term (week 16) but not during short-term (week 4). However, it did not influence plasma 
and intracellular concentrations of EFV during short-term but only with a trend during long 
term (P=0.07). UGT2B7 genotype significantly affected plasma concentration of 8-OH-EFV 
and EFV MR and a significant trend in EFV concentration over time. This within-subject 
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variability was pronounced among *2/*2 but not *1/*1 genotypes. However, CYP3A5 and 
ABCB-1 3435C >T genotypes did not significantly affect both between and within-subject 
variabilities in plasma and intracellular pharmacokinetics of EFV. 
Pearson and Spearman correlation tests indicated a significant positive correlation between the 
plasma and intracellular concentrations of EFV and the EFV MR at both weeks 4 and 16. 
Besides, a significant correlation between plasma and intracellular concentrations of 8-OH-
EFV at week 4 (P=0.02), but not at week 16 (P=0.44) was shown.  
The extent of change in plasma concentrations of 8-OH-EFV over time was significantly 
affected by sex (repeated measures ANOVA, P=0.015), where females at week 16 displayed 
higher concentrations than the respective value at week 4. Considering male and females 
separately, there was a significant increase in the 8-OH-EFV level (P=0.0001) and a decrease 
in the EFV MR (P=0.001) in females at week 16 compared to week 4. However, no significant 
change was observed in males (P=0.20 and P=0.74, respectively). In addition, sex had no 
significant effect on the intracellular EFV concentration at week 4, but displayed a tendency to 
influence it at week 16 (P=0.08). 
4.1.2. Effect of plasma and intracellular efavirenz pharmacokinetics on CD4 count over 
time  
Regression analysis revealed that plasma concentration of EFV at week 4 predicted CD4 count 
at week 24 (P=0.01, F=5.43) and a trend at week 12 (P=0.09) but not at week 48 (P=0.75). In 
addition, the plasma concentration of EFV at week 4 significantly affected within-subject 
variability in the CD4 count (change over time). EFV plasma concentration at week 4 
influenced the change in CD4 count from baseline until week 12 (P=0.038). Inclusion of 
intracellular and plasma EFV concentrations at weeks 4 and 16 in a stepwise forward 
regression model, the intracellular concentration at week 16 was found to be a significant 
predictor of CD4 count at week 24 (F=6.36, P=0.01).  
4.1.3. Effect of pharmacogenetic variations on the change in CD4 counts over time 
Friedman two-way ANOVA indicated significant increases in CD4 count (P=0.0001) from 
baseline over time during the 48 weeks treatment with efavirenz-based HAART in all patients.  
Significant within-subject variability was shown: week 0 versus week 12 (P=0.0001); week 12 
versus week 24 (P=0.08); and week 24 versus week 48 (P=0.028).  
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Regardless of sex or genotype differences, there was a sharp increase in the CD4 counts from 
baseline until week 12. However, the pattern of change in the CD4 count was different between 
the different CYP2B6 and UGT2B7 genotype groups after week 24. Among the CYP2B6*1/*1 
and UGT2B7*1/*1 genotype groups there was no significant change after week 24, whereas 
the mean CD4 count continued to increase until week 48 among CYP2B6*6/*6 and 
UGT2B7*2/*2 genotype groups.  
Sex, CYP2B6, CYP3A5, UGT2B7, ABCB1 genotypes were included in a forward stepwise 
regression model, but none of them predicted CD4 count at week 24, but CYP2B6 (P=0.02) and 
UGT2B7 became significant predictors of CD4 count at week 48.  
4.2. Pharmacogenetic and pharmacokinetic influences of efavirenz on 
CYP3A induction (Paper II) 
4.2.1. Change in 4β-hydroxy-cholesterol metabolic ratio over time  
The median plasma 4β-OHC concentration was increased by 1.4-, 1.8- and 3.5-fold at weeks 4, 
16 and 48, respectively. Compared with the baseline value, the median plasma 4β-OHC/Chol 
ratios increased by 2.6-, 2.9- and 1.7-fold at weeks 4, 16 and 48, respectively (Friedman two-
way ANOVA test, P=0.0001). Dunn’s multiple comparison test of pairwise contrast from 
baseline indicated a significant increase in the median 4β-OHC/Chol ratios (P=0.001) at each 
study time point. Despite the constant increase in 4β-OHC concentrations, the median plasma 
4β-OHC/Chol ratio at week 48 was lower than week 16 merely due to the relatively larger 
increase in the denominator cholesterol concentration.  
4.2.2. Effect of sex and pharmacogenetic factors on between and within subject 
variability of 4β-hydroxy-cholesterol metabolic ratio  
Kruskal–Wallis one-way ANOVA was used to investigate effects of genotype on between-
subject variability of plasma 4β-OHC/Chol ratios at each time point. None of the investigated 
genotypes including CYP3A5 had a significant effect except the CYP2B6 genotype whose 
influence became apparent and significant at weeks 16 and 48 but had no effect at baseline or 
at week 4. The within subject contrast test between adjacent concentrations indicated a 
significant effect of the CYP2B6 genotype on the change in 4β-OHC/Chol ratio (P=0.029, 
F=3.71). Friedman two-way ANOVA indicated that there were significant differences in the 
extent of change in 4β-OHC/Chol ratio over time between the different CYP2B6 genotypes; 
being highest in CYP2B6*6/*6 > *1/*6 > *1/*1 genotypes (P=0.04). The level increased 
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significantly in carriers of the CYP2B6*6 allele at weeks 16 and 48. No effect of sex and 
CYP3A5, ABCB1 and UGT2B7 genotypes was shown on the short- or long-term induction of 
CYP3A.   
4.2.3. Correlation between plasma efavirenz & 4β-OHC/Chol ratio concentrations 
There was a significant positive correlation between 4β-OHC/Chol ratio and plasma EFV 
concentration both at week 4 (P=0.02, r2=0.08) and at week 16 (P=0.001; r2=0.17. The higher 
the plasma EFV concentration, the higher the respective 4β-OHC/Chol ratio.  
4.3. Impacts of ethnicity and pharmacogenetic factors on pharmacokinetics 
of efavirenz and immunologic outcomes (Paper III) 
4.3.1. Comparisons of allele frequencies and efavirenz concentrations between 
 Ethiopia and Tanzania populations 
Genotype frequencies were determined in Ethiopian (n=262) and Tanzanian patients (n=184). 
Haplotype analyses indicated no linkage between CYP3A5 SNPs. The frequencies of all 
variant alleles determined in this study such as CYP2B6, CYP3A5, UGT2B7, ABCB1 and 
SLCO1B1 genes were significantly different between the two populations.  
Independent t-test indicated higher mean log plasma EFV concentration in Tanzanians than 
Ethiopians at both weeks 4 (P<0.0001) and 16 (P=0.002). Within country analyses using paired 
samples t-test revealed significant decrease in the mean plasma EFV concentration over time in 
Tanzanians (p=0.006), but not in Ethiopians (P=0.84). Univariate analysis indicated the 
following as significant predictors of  plasma efavirenz concentrations (percent explained 
variability, P value); CYP2B6*6 genotype (10.7%, P < 0.0001) patient country (4%, P < 
0.0001), co-infection with Hepatitis B at recruitment (1.3%, P=0.001), CYP3A5 genotype 
(0.8%, P=0.02), ABCB1 3435C >T (0.7%, P=0.02), ABCB1 3842A>G (0.98%, P=0.01), 
SLCO1B1D130N (0.7%, P=0.02), SLCO1B1 A174V (0.6%, P=0.031).  
4.3.2. Influences of ethnicity, pharmacogenetic and other factors on plasma and 
intracellular concentrations of efavirenz  
Time on therapy (week at which EFV plasma levels assessed) was not a significant predictor 
(p=0.3557). However, time on EFV therapy showed significant interaction with country 
(p=0.02). Therefore, further assessments of factors affecting EFV plasma level at week 4 and 
week 16 were done separately. 
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Univariate linear regression analysis identified the following variables as predictors of EFV 
plasma concentration at week 4; CYP2B6*6 genotype (9.8%, p<0.0001), country (4.8%, 
p<0.0001), co-infection with Hepatitis B at recruitment (0.6%, p=0.061), CYP3A5 genotype 11 
(1.5%, p=0.019), ABCB1 3435C>T (0.8%, p=0.082), ABCB1 3842 A>G (2.4%, p=0.003), 
SLCO1B1 D130N (0.8%, p=0.084). Multivariate regression analysis for EFV plasma 
concentration at week 4: CYP2B6 genotypes (p<0.0001), country (p=0.035) and ABCB1 3842 
A>G genotypes (p=0.002) were associated with significant increase in model explained inter-
individual variability of week 4 plasma concentration of EFV. The overall model explained for 
16% of inter-individual variability in week 4 plasma concentrations of EFV (p<0.0001). When 
models were built for each country separately, CYP2B6*6 contributed 8.3% and 11% while 
ABCB1 3842 A>G contributed 0.6% and 8.3% of the inter-individual variability in week 4 
plasma EFV concentration in Ethiopian and Tanzanian patients, respectively. 
Similarly, Univariate linear regression identified the following variables as predictors (r2, p 
value) of EFV plasma concentration at week 16; CYP2B6*6 genotype (17.9%, p<0.0001), 
country (2.5%, p<0.0001), co-infection with Hepatitis B at recruitment (2.6%, p=0.003). Only 
CYP2B6*6 genotypes (p<0.0001) and baseline hepatitis B co-infection (p=0.002) were 
associated with significant increase in model explained inter-individual variability of week 16 
EFV plasma concentration. Country had a trend to influence variability (p=0.08). The model 
explained for 20% of inter-individual variability in week 16 plasma EFV concentrations 
(p<0.0001). On separate model building for each country, CYP2B6*6 contributed 13.3% and 
20.6% of inter-individual variability in EFV plasma concentration at week 16 in Ethiopian and 
Tanzanian patients, respectively. 
Factors influencing EFV intracellular concentrations individually at week 4 were; EFV plasma 
concentrations (29.2%, p<0.0001), country (11.9%, p<0.0001), CYP2B6*6 genotypes (4%, 
p=0.02), body mass index (2.2%, p=0.009), baseline ALT levels (1.9%, p=0.014), SLCO1B1*5 
(1.8%, p=0.039), SLCO1B1*1b (1.5%, p=0.056) and CYP3A5 (3.6%, p=0.004). In 
multivariate model, only EFV plasma concentrations at week 4 (p<0.0001) and country (p= 
0.041) remained significant predictor of intracellular EFV concentrations at week 4.  
Factors influencing EFV intracellular concentrations individually at week 16 were; EFV 
plasma concentration at week 16 (25%, p<0.0001), country (10.2%, p<0.0001), CYP2B6*6 
(6.9%, p<0.0001), SLCO1B1 D130N (*1b) (2.1%, p=0.034), SLCO1B1 A174V (*5) (1.5%, 
p=0.056) baseline Hepatitis B co-infection (2.1% p=0.014). However, only EFV plasma 
concentrations at week 16 and country were significant predictors of the intracellular EFV 
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concentrations. The model explained for 32.4% of inter-individual variability in week 16 
intracellular EFV concentration (p<0.0001). 
4.3.3. Effect of ethnicity and CYP2B6 genotype on immunologic outcomes   
At weeks 24 (p=0.004) and 48 (p=0.002) of EFV therapy, the mean CD4 cell count was 
significantly higher in Tanzanians than Ethiopians. Within subject tests of repeated measure 
ANOVA showed a significant increase in CD4 over time (p<0.0001). Bonferroni post hoc test 
indicated that major increases were between week 0 and 12 (p<0.0001) and between week 24 
and 48 (p=0.008). No significant difference was shown between week 12 and 24 (p=0.57).  
Between subject effect tests of repeated measure ANOVA showed a significant effect for 
country (p=0.004) but not CYP2B6 (p=0.29). Splitting the data by country, between subject 
effect test for CYP2B6 genotype was not significant for Tanzanians (p=0.52). However, a trend 
of having higher CD4 gain for being carrier of CYP2B6*6 allele in gene-dose dependent 
manner for Ethiopians (p=0.11). Having the same CYP2B6 genotype, Tanzanians displayed 
higher CD4 gain than Ethiopians except in CYP2B6*6 genotype groups. Multivariate linear 
regression model building indicated intracellular EFV concentrations at week 4 (p=0.013) was 
a significant predictor of CD4 gain by week 12, while patient country (p=0.059) had a trend. 
4.4. Effects of efavirenz pharmacokinetic & pharmacogenetic factors on 
drug-induced liver injury (DILI) (Paper IV) 
4.4.1. Effect of efavirenz concentration on DILI 
Significant associations were shown between DILI and increased plasma EFV 
concentration/EFV MR (p=0.036).  
4.4.2. Associations of CYP2B6, ABCB1 and NAT2 genotypes with DILI 
Cox-regression analysis showed that there was a statistically significant association between 
DILI with CYP2B6*6, ABCB1 3435TT and NAT2 slow-acetylator genotypes (p=0.04, 0.02 
and 0.039 respectively). There was significant difference in the proportion of subjects with 
ABCB1 3435TT genotype between cases (12.2%) and controls (3.8%) wherein the proportion 
was higher in those who developed DILI. A nearly significant effect of UGT2B7*2/*2 
genotype with DILI was also noted (P=0.08).  
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4.5. Influence of rifampicin co-therapy on plasma/intracellular efavirenz 
pharmacokinetics & immunologic and virologic outcomes of HAART. 
(Paper V)  
4.5.1. Effect of rifampicin co-treatment on plasma/intracellular concentrations of 
efavirenz 
Independent t-test revealed that early in co-therapy (week 4), plasma concentration of EFV was 
higher in patients receiving EFV concomitantly with RIF co-treatment (Arm 2) than patients 
receiving EFV only (Arm 1) (p=0.04). Similar difference was noted, though a trend (p=0.1) 
during later stage of co-treatment. A nearly significant higher EFV intracellular concentration 
was observed in RIF co-treatment group than without RIF at week 4 (p=0.08) but no difference 
was seen at week 16. Stratifying patients based on baseline body weight, no difference was 
seen in plasma concentrations of EFV between the two arms at both occasions (weeks 4 and 
16) among patients with body weight less than 50Kg. On the contrary, higher plasma EFV 
concentrations were shown in RIF co-treatment group than without RIF at both occasions 
(weeks 4 and 16) among patients with body weight greater than or equal to 50Kg at baseline.  
Stratifying patients by CYP2B6, higher EFV plasma concentrations were noted in RIF co-
treatment group than without RIF at week 4 (p=0.04) and a similar trend (p=0.1) was seen at 
week 16 among CYP2B6*6 carriers. However, no difference was shown between the groups at 
both occasions among CYP2B6*1/*1 genotype. Regardless of CYP2B6 genotype stratification, 
there was no difference in EFV intracellular concentration between RIF co-treatment group and 
the group without RIF at both occasions. 
4.5.2. Predictors of plasma and intracellular concentrations of efavirenz 
Factors affecting log plasma efavirenz concentrations at week 4 and week 16 separately were 
analyzed using regression analysis. Treatment group, demographic, type of HAART, baseline 
biochemical parameters, and CYP2B6 genotype were used as predictors and plasma EFV 
concentrations as dependent variable. Factors that influence log plasma concentrations of EFV 
with p<0.3 in the Univariate were included in multivariate linear regression model to build the 
final model. Backward elimination method was used to obtain predictors in the final 
multivariate linear regression model. Treatment group (Arm), sex and CYP2B6 genotype 
remained significant predictors of plasma efavirenz concentration at both week 4 and 16 but 
not body baseline body weight categorization. 
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4.5.3. Immunologic and virologic outcome comparisons between HIV and TB-HIV co-
treatment groups 
Repeated measure ANOVA indicated a tendency of having higher median CD4 over time in 
Arm-2 (TB-HIV co-infected) patients compared (p=0.06). However repeated measure ANOVA 
within each treatment group did not show significant effect of baseline body weight groups on 
change in CD4 cell count over time. Immunologic response to EFV-based HAART was higher 
among individuals co-treated with RIF containing anti-TB regimen than without. Having the 
same CYP2B6 genotypes, patients’ co-treated with RIF displayed higher CD4 gain than those 
treated with EFV-based HAART only.   
Univariate regression analyses were done on CD4 count at week 24 as outcome variable. 
Factors in final models predicting efavirenz plasma concentration were, Arm (p=0.0001) and 
HBsAg (p=0.02) at week 4 and Arm (p=0.0001), HBsAg (p=0.02), and CYP2B6 genotypes 
(P=0.02) at week 16 predicted CD4 count at week 24. Among efavirenz intracellular 
concentration predictors, Arm (p=0.05), Sex (p=0.001), Baseline BMI (p=0.02) and CYP3A5 
genotypes (p=0.07) at week 4 affected CD4 count at week 24.  
Proportion of patients with detectable HIV RNA (> 50 copies/mL) at week 24 was significantly 
lower among HIV patients receiving EFV based HAART alone (9%) than TB-HIV co-infected 
patients receiving concomitant RIF co-therapy (23%), regardless of baseline body weight 
category. No significant differences in the proportion of HIV virologic responders were 
observed at 48 weeks between the two treatment groups and stratified by body weight category. 
To evaluate relationships between EFV concentration, presence or absence of RIF co-therapy 
(Arm) and baseline body weight category, we performed Univariate and multivariate binary 
logistic regression analysis. No significant effect of plasma EFV concentration or CYP2B6 
genotype on virologic response was observed at both study time points. Baseline body weight, 
presence of TB co-infection and RIF co-treatment had significant effect on virologic response 
at week 24 but not at week 48. The effect of baseline body weight on virologic response was 
observed, irrespective of presence or absence of RIF co-treatment. 
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5. DISCUSSION 
This thesis reports several major findings. One of the main findings of this thesis is paradoxical 
effect of rifampicin (RIF) co-therapy on plasma and intracellular concentrations of efavirenz 
(EFV), consistent to this, improved immunologic response to HAART is reported among RIF 
co-treated cohort than without. These effects were pronounced among CYP2B6 slow 
metabolizers or CYP2B6*6 carriers (Paper V). In addition, there was no difference in the 
proportions of virologic successes between the two groups, irrespective of pretreatment body-
weight (Paper V). The thesis also reports substantial between subject variability in the effect of 
long-term efavirenz (EFV) auto-induction, systemic plasma and intracellular exposures of EFV 
as well as treatment response over time, partly due to time-dependent effects of sex, CYP2B6 
and UGT2B7 genotypes (Paper I). In addition, this thesis reports that induction of CYP3A by 
EFV is concentration and time-dependent and influenced by CYP2B6 genotypes in a gene-dose 
dependent manner (Paper II). The thesis also demonstrates importance of ethnicity and 
environmental factors, besides pharmacogenetic variations in CYP2B6 and ABCB1 genotypes 
to substantially contribute differences in EFV plasma/intracellular systemic exposure as well as 
immunologic recovery between Ethiopian and Tanzanian HIV patients receiving similar 
HAART (Paper III). Moreover, this thesis reveals associations of elevated EFV plasma 
concentration and pharmacogenetic biomarkers such as ABCB1 3435TT, CYP2B6*6/*6 and 
NAT2 slow-acetylator genotypes with the development DILI in Ethiopian TB-HIV co-infected 
patients (Paper IV).  
Pharmacokinetic studies reported reduced plasma exposures of EFV due to co-administration 
of RIF, owing to the ubiquitous enzyme inducing nature of RIF [42]. To the effect, escalation 
of EFV dose from 600mg to 800mg was recommended when EFV was co-administered with 
RIF [171]. However, recent studies from diverse population rebut the dose escalation 
recommendation [57, 93, 161, 172-174]. In agreement with the later, the thesis does not 
recommend escalation of EFV dose in TB-HIV co-infected Ethiopian patients through this 
thesis with pharmacokinetic supported TB-HIV treatment outcomes (Paper V).  
Proportion of patients with detectable HIV RNA viral load (>50 copies/mL) was significantly 
higher in EFV group by week 24 irrespective of baseline body weight category (Paper V). 
However, there was no difference in proportions of virologic responders between groups 
containing EFV-based HAART only and RIF co-treatment with EFV-based HAART by week 
48, indicating that concurrent TB-HIV co-treatment takes longer time to reach virologic 
success compared to treating HIV only infection (Paper V). Besides, analysis indicated higher 
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proportion of patients with detectable HIV RNA viral load in those weighting > 50 kg at 
baseline as compared to those weighing ≤ 50kg in both EFV-based HAART only and RIF co-
treatment with EFV-based HAART groups. This might indicate that effect of pretreatment 
body weight on viral response is not specific to presence of rifampicin co-treatment (Paper V). 
By and large, Sub-Saharan countries obtain ARV drugs through donations from various 
international initiatives. The above pharmacokinetic and pharmacodynamic findings in the 
thesis highlight the use of standard dose of EFV during TB-HIV co-treatments, irrespective of 
pretreatment body-weight to minimize dose-related EFV toxicities, in addition to the cost 
reductions that could have been incurred due to EFV dose-escalation from 600mg to 800mg.  
The thesis also reveals the long-term auto-inductions by EFV, as evident by the significant 
increase in the main metabolite, 8-hydroxyefavirenz (8-OH-EFV), in plasma (32%) and in 
PBMCs (53%) with a corresponding decrease in EFV metabolic ratio (20% and 5%, 
respectively) over time. The extent of change was significantly affected by sex, CYP2B6 and 
UGT2B7 genotypes (Paper I). EFV is primarily metabolized to 8-OH-EFV mainly by 
CYP2B6, also by others such as CYP1A2, CYP3A5/4 and CYP2C9 [158, 159]. Auto-induction 
of EFV may involve some if not all of these enzymes as most of them are inducible [175-177]. 
The long-term auto-induction effect of EFV on CYP3A was reported in this thesis, using an 
endogenous biomarker for CYP3A activity, 4β-OHC/Chol ratio (Paper II). Besides, the auto-
induction on CYP3A by EFV was shown to be influenced by CYP2B6 genotype in gene-dose 
dependent manner, being highest in slow metabolizers with CYP2B6*6/*6 genotype followed 
by *1/*6 and *1/*1. This was further substantiated by a positive correlation, though weak, 
between plasma EFV concentration and 4β-OHC/Chol ratio both at two different times (Paper 
II). The implication of long-term auto-inductions by EFV may warrant potential DDIs between 
EFV and substrates to CYP3A and CYP2B6 enzymes.    
The plasma and intracellular concentrations of EFV did not change significantly over time, 
despite changes in 8-OH-EFV and EFV MR over time, as above (Paper I). This is in contrast 
to a report on Tanzanian HIV patients, where there was an overall significant reduction in the 
EFV concentration over time [176]. The two studies were designed and conducted in parallel to 
investigate the effect of EFV auto-induction on its systemic exposure over time in two 
pharmacogenetically different African populations. This thesis indicates not only the presence 
of inter-individual but also interethnic variation in the extent of EFV auto-induction. EFV 
pharmacokinetic variability is not solely explained by the 8-hydroxylation pathway or the 
CYP2B6 genotype, because large between-subject variability in the plasma EFV exposure 
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remains unexplained, even after accounting for known CYP2B6 genetic variations. This was 
the basis for evaluation and identification of predictors of plasma and intracellular 
concentrations of EFV by combining the similarly designed and parallelly conducted data from 
Ethiopian and Tanzanian HIV patients (Paper III).   
The thesis reports that geographic differences (patient country), CYP2B6*6 and ABCB1 3842 
A < G genotypes as significant predictors of EFV plasma and intracellular concentration 
(Paper III). The allele frequency distributions of both CYP2B6*6 and ABCB1 3842A<G 
alleles was significantly higher in Tanzanians than Ethiopians. Likewise EFV plasma and 
intracellular concentrations as well as immunological gain were significantly different between 
the two populations; being higher in Tanzanians than Ethiopians (Paper III). Besides, the 
extent of EFV auto-induction overtime was pronounced in Tanzanians whereas no significant 
change was observed in Ethiopians (Papers I & III). This thesis demonstrates not only the 
existence of between population differences in EFV pharmacokinetics and pharmacogenetics 
but also variations in the extent of EFV auto-induction between populations (Paper III). 
Furthermore, to optimize EFV dosage, the thesis emphasizes the importance of ethnicity and 
environment factors in addition CYP2B6 and ABCB1 genotype, which may in turn influence 
the immunological outcomes (Paper III). This is in line with the results by Dandara et al [111] 
who also found inter-ethnic and population differences in the distribution of various allele 
frequencies for other CYPs among Africans. This thesis reaffirms the need for extensive 
population specific pharmacogenetic research for optimized antiretroviral therapy across 
Africa. 
The thesis also reports the association of elevated plasma concentration of EFV with DILI 
(Paper IV). The association of higher EFV plasma concentration with DILI was regardless of 
concomitant RIF based anti-TB therapy, whereas no association of the metabolite (8-
hydroxyefvairenz) was observed. Furthermore, ABCB1 3435TT, CYP2B6*6/*6 and NAT2 
slow-acetylator genotypes were identified as pharmacogenetic biomarkers for the development 
DILI in Ethiopian TB-HIV co-infected patients (Paper IV). Direct liver toxicity by higher EFV 
plasma concentration could be a possible mechanism for EFV-based HAART induced liver 
injury in HIV patients. In support of this argument were associations of DILI with CYP2B6*6 
and UGT2B7*2, the variant alleles associated with increased EFV plasma concentration 
(Paper IV). The associations of these genetic biomarkers with DILI emphasize the need to use 
pharmacogenetic tools to predict and identify HIV treatment toxicities a priori.       
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In addition to the above major findings, this thesis also reports several outcomes. One of the 
results reported in the thesis is the following allele frequencies in Ethiopian population: 
CYP2B6*6, CYP3A5*3, CYP3A5*6, UGT2B7*2, ABCB1 3435C >T, ABCB1 3842A<G, 
SLCO1B1-D130N (*1b), SLCO1B1-A174V (*5) were 29.7%, 66.9%, 10.6%, 48.1%, 20.9%, 
14.5%, 61.1% and 79.1%  respectively (Papers I & III). Besides reporting these allele 
frequencies in Ethiopian population as new information, the comparisons of the allele 
frequencies between the two sub-Saharan African countries, the thesis also shows significant 
differences between Ethiopians and Tanzanians, reaffirming the need for extensive population 
specific pharmacogenetic studies to optimized antiretroviral therapy across Africa (Paper III).  
The thesis also shows positive correlations of plasma and intracellular concentrations of EFV 
(Paper I). Most ARV drugs including EFV are known to exert their effect intracellularly [178, 
179]. Drug concentrations at the site of action are regarded as the true indicative for treatment 
successes. The result of the correlation between plasma and intracellular concentrations of EFV 
suggested that plasma exposure could be surrogate marker for intracellular activity (Paper I). 
This is in agreement with previous reports [180, 181]. This thesis also reports higher incidence 
of drug induced liver injury (DILI) due to concomitant anti-TB and EFV-based HAART 
among TB-HIV co-infected Ethiopian patients (Paper IV).  
This thesis also demonstrates the influence of pharmacogenetic variations on immunologic 
outcome among HIV infected Ethiopians (Paper I). By and large, good immune recovery, as 
indicted by a sharp increase in the CD4 count during early (3 months) on HAART. This was 
regardless of sex or genotype (Paper I). However, the pattern of CD4 gain was observed to be 
variable between the different CYP2B6 and UGT2B7 genotype groups 6 and 12 months after 
HAART. There was no significant change in the CD4 count between 6 and 12 months among 
subjects with CYP2B6*1/*1 and UGT2B7*1/*1, while the CD4 count continued to increase 
among carriers of CYP2B6*6/*6 and UGT2B7*2/*2 (Paper I). The thesis indicates that the 
effect of genetic variation in CYP2B6 and UGT2B7 on the change in the CD4 count becomes 
apparent in the long run as therapy continues (Paper I). Genotype variability may be 
considered as additional factor to explain differences in immunologic response for HAART. 
The thesis pioneers to stratify immunologic outcomes of EFV-based HAART based on 
genotypes. 
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6. CONCLUSIONS AND RECOMMENDATIONS 
6.1. Conclusions 
• Rifampicin (RIF) co-therapy caused paradoxical effect of plasma and intracellular 
concentrations of efavirenz (EFV), subsequent to that it caused better immunologic 
response and comparable virologic success to HAART than HAART without RIF.  
• Substantial between-subject variability was shown in the effect of long-term efavirenz 
(EFV) auto-induction, systemic plasma and intracellular exposures of EFV and 
HAART response over time, partly due to time-dependent effects of sex, CYP2B6 and 
UGT2B7 genotypes. 
• Induction of CYP3A by EFV was influenced by CYP2B6 genotypes in concentration 
and time-dependent in a gene-dose dependent manner. 
• Importance of ethnicity and environmental factors substantially contributed to the 
differences in EFV plasma/intracellular systemic exposure as well as immunologic 
recovery. 
• Associations of elevated EFV plasma concentration and ABCB1 3435TT, CYP2B6*6/*6 
and slow NAT2 metabolizing genotypes with the development of DILI in Ethiopian TB-
HIV co-infected patients were observed. 
• Allele frequencies of CYP2B6*6, CYP3A5*3, CYP3A5*6, UGT2B7*2, ABCB1 3435C 
>T, ABCB1 3842A>G, SLCO1B1 D130N (*1b), SLCO1B1 A174V (*5) in Ethiopian 
population were reported.  
• Positive correlation between plasma and intracellular concentrations of EFV was 
established. 
• Impact of pharmacogenetic variations on immunologic outcome among HIV infected 
Ethiopians was demonstrated.  
• RIF co-therapy, Baseline Body Weight and CYP2B6 genotypes predicted plasma and 
intracellular concentrations of EFV during short-term and long-term EFV 
administration. Among these factors, RIF co-therapy and CYP2B6 genotypes were 
associated with CD4 recovery at 6 months EFV-based HAART. 
6.2. Recommendations  
• Escalation of efavirenz (EFV) dose from 600mg to 800mg is not needed in co-treating 
TB/HIV co-infected Ethiopian. 
• Potential drug-drug interactions may be warranted on substrates of CYP3A and CYP2B6 
enzymes due to long-term induction effect of EFV.  
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• Extensive population specific pharmacogenetic studies for optimized antiretroviral 
therapy across Africa should be carried out. 
• Therapeutic drug monitoring (TDM) in association with pharmacogenetic tools may be 
employed to routinely monitor HAART toxicities and responses.                    
• Plasma concentrations of EFV may be surrogate markers for intracellular EFV 
exposure.  
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